MedTrace Logo

Buyang Huanwu Decoction With Wuling Powder for Acute Ischemic Stroke

NCT07687043 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2026-07-07

No results posted yet for this study

Summary

Acute ischemic stroke is a common cause of disability. Standard Western medical treatment is widely used, but some patients continue to have neurological impairment and difficulty with daily activities after stroke.

This study evaluated whether Buyang Huanwu Decoction combined with Wuling Powder, when added to standard Western medical treatment, could help improve recovery in patients with acute ischemic stroke. Eligible patients were randomly assigned to receive either standard Western medical treatment alone or standard Western medical treatment plus Buyang Huanwu Decoction combined with Wuling Powder for 14 days.

The study assessed neurological function, activities of daily living, disability outcomes, and short-term safety. Blood samples were also collected to explore changes in serum metabolites and redox-related biomarkers that may be related to treatment response. A non-stroke reference group was included only for serum metabolomic comparison and was not part of the randomized treatment comparison.

Conditions

  • Acute Ischemic Stroke

Interventions

PROCEDURE

Standard Western Medical Treatment

Standard guideline-based medical care for acute ischemic stroke.

OTHER

Serum Sample Collection for Metabolomics Only

Blood samples collected for metabolomic profiling only.

DRUG

Buyang Huanwu Decoction Combined With Wuling Powder

14-day oral decoction, twice daily, composed of Astragali Radix, Angelicae Sinensis Radix, and other herbs as specified.

PROCEDURE

Standard Western Medical Treatment

Guideline-based acute ischemic stroke management.

Sponsors & Collaborators

  • Liaoning University of Traditional Chinese Medicine

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-20
Primary Completion
2025-04-20
Completion
2025-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07687043 on ClinicalTrials.gov